No Data
No Data
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Express News | Apellis Pharmaceuticals Inc : UBS Cuts Target Price to $83 From $85
Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Price Target Raised to $74.00/Share From $66.00 by Goldman Sachs
Mizuho Adjusts Apellis Pharmaceuticals' PT to $42 From $40, Keeps Neutral Rating
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
No Data